Liu J - Search Results

1

AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas.

May CD, Garnett J, Ma X, Landers SM, Ingram DR, Demicco EG, Al Sannaa GA, Vu T, Han L, Zhang Y, Kivlin CM, Bolshakov S, Kalam AA, Liu J, Zhou F, Broccoli D, Wang WL, Lazar AJ, Pollock RE, Lev D, Torres KE. May CD, et al. Among authors: liu j. BMC Cancer. 2015 Nov 14;15:901. doi: 10.1186/s12885-015-1916-3. BMC Cancer. 2015. PMID: 26573603 Free PMC article.

2

Transcriptional repression of protein kinase Calpha via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation.

Zhan M, Yu D, Liu J, Glazer RI, Hannay J, Pollock RE. Zhan M, et al. Among authors: liu j. J Biol Chem. 2005 Feb 11;280(6):4825-33. doi: 10.1074/jbc.M407450200. Epub 2004 Nov 24. J Biol Chem. 2005. PMID: 15563462 Free article.

3

Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance.

Zhang L, Hannay JA, Liu J, Das P, Zhan M, Nguyen T, Hicklin DJ, Yu D, Pollock RE, Lev D. Zhang L, et al. Among authors: liu j. Cancer Res. 2006 Sep 1;66(17):8770-8. doi: 10.1158/0008-5472.CAN-06-1217. Cancer Res. 2006. PMID: 16951193

4

Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation.

Hannay JA, Liu J, Zhu QS, Bolshakov SV, Li L, Pisters PW, Lazar AJ, Yu D, Pollock RE, Lev D. Hannay JA, et al. Among authors: liu j. Mol Cancer Ther. 2007 May;6(5):1650-60. doi: 10.1158/1535-7163.MCT-06-0636. Mol Cancer Ther. 2007. PMID: 17513613

5

Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma.

Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G, Zhu QS, Bornmann WG, McConkey DJ, Pollock RE, Lev DC. Lopez G, et al. Among authors: liu j. Clin Cancer Res. 2009 May 15;15(10):3472-83. doi: 10.1158/1078-0432.CCR-08-2714. Epub 2009 May 5. Clin Cancer Res. 2009. PMID: 19417021

6

Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.

Lopez G, Torres K, Liu J, Hernandez B, Young E, Belousov R, Bolshakov S, Lazar AJ, Slopis JM, McCutcheon IE, McConkey D, Lev D. Lopez G, et al. Among authors: liu j. Cancer Res. 2011 Jan 1;71(1):185-96. doi: 10.1158/0008-5472.CAN-10-2799. Epub 2010 Nov 16. Cancer Res. 2011. PMID: 21084276 Free PMC article.

7

Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.

Torres KE, Zhu QS, Bill K, Lopez G, Ghadimi MP, Xie X, Young ED, Liu J, Nguyen T, Bolshakov S, Belousov R, Wang S, Lahat G, Liu J, Hernandez B, Lazar AJ, Lev D. Torres KE, et al. Among authors: liu j. Clin Cancer Res. 2011 Jun 15;17(12):3943-55. doi: 10.1158/1078-0432.CCR-11-0193. Epub 2011 May 3. Clin Cancer Res. 2011. PMID: 21540237 Free PMC article.

8

Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma.

Xie X, Ghadimi MP, Young ED, Belousov R, Zhu QS, Liu J, Lopez G, Colombo C, Peng T, Reynoso D, Hornick JL, Lazar AJ, Lev D. Xie X, et al. Among authors: liu j. Clin Cancer Res. 2011 Sep 15;17(18):5901-12. doi: 10.1158/1078-0432.CCR-11-0660. Epub 2011 Aug 5. Clin Cancer Res. 2011. PMID: 21821699 Free PMC article.

9

MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling.

Zhang P, Bill K, Liu J, Young E, Peng T, Bolshakov S, Hoffman A, Song Y, Demicco EG, Terrada DL, Creighton CJ, Anderson ML, Lazar AJ, Calin GG, Pollock RE, Lev D. Zhang P, et al. Among authors: liu j. Cancer Res. 2012 Apr 1;72(7):1751-62. doi: 10.1158/0008-5472.CAN-11-3027. Epub 2012 Feb 20. Cancer Res. 2012. PMID: 22350414 Free PMC article.

10

Editor's Note: Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma.

Xie X, Ghadimi MPH, Young ED, Belousov R, Zhu QS, Liu J, Lopez G, Colombo C, Peng T, Reynoso D, Hornick JL, Lazar AJ, Lev D. Xie X, et al. Among authors: liu j. Clin Cancer Res. 2024 Feb 16;30(4):921. doi: 10.1158/1078-0432.CCR-23-3969. Clin Cancer Res. 2024. PMID: 38362726 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

136,395 results

Search Page